PACB Stock News & Analysis | Latest Updates

PacBio Completes Sale of Short-Read Sequencing Assets

MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of select intellectual property and other assets related to PacBio’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina, Inc.

February 2, 2026

PACB News

PacBio Completes Sale of Short-Read Sequencing Assets

PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq Workflow

PacBio Biosciences Of California Announces China Distributor To Expand Access To Its HiFi Long-Read Sequencing Technology In Clinical And Research Settings

Piper Sandler Maintains Neutral on Pacific Biosciences, Lowers Price Target to $1.25

Where Pacific Biosciences Stands With Analysts

Stephens & Co. Reiterates Overweight on Pacific Biosciences, Maintains $1.8 Price Target

PacBio Independent Investigation Finds No Issues in Employment & Cybersecurity Matters

Pacific Biosciences Q1 Adj. EPS $(0.15) Beats $(0.19) Estimate, Sales $37.15M Beat $34.81M Estimate

PacBio Announces Strategic Collaboration To Implement PacBio HiFi Whole Genome Sequencing As Part Of Newborn Screening Research Program

Davos Alzheimer's Collaborative Announces PacBio Will Be A Technology Partner To Its North African Dementia Registry Project

Canaccord Genuity Maintains Buy on Pacific Biosciences, Maintains $3 Price Target

Sequencing Company PacBio Cuts Costs Amid Uncertainty Around NIH Funding And New Tariffs

PacBio Says In Response To Ongoing Market Uncertainty, PacBio Is Executing A Plan To Reduce Both Headcount Across All Functions And Non-Headcount Related Expenses To Lower Its Annualized Non-GAAP Operating Expense Run-Rate By $45M-$50M

PacBio Sees Prelim. Q1 Revenue $36.9M, Reiterates 2025 Revenue Guidance

PacBio Appoints Jim Gibson As CFO, Effective Start Date Mar. 31

Assessing Pacific Biosciences: Insights From 6 Financial Analysts

Scotiabank Maintains Sector Outperform on Pacific Biosciences, Lowers Price Target to $2

Piper Sandler Reiterates Neutral on Pacific Biosciences, Lowers Price Target to $2

Where Pacific Biosciences Stands With Analysts

Goldman Sachs Maintains Neutral on Pacific Biosciences, Lowers Price Target to $1.5

Stephens & Co. Reiterates Overweight on Pacific Biosciences, Maintains $2.5 Price Target

Pacific Biosciences Q4 Adj $(0.20) Beats $(0.21) Estimate, Sales $39.22M Miss $40.16M Estimate

Pacific Biosciences Sees Prelim. Q4 Revenue ~$39.2M Vs $40.536M Est.

PacBio and Intus Bio Launch GutID: First AI-Powered, HiFi Sequencing Gut Microbiome Test

How Is The Market Feeling About Pacific Biosciences?

Recap: Pacific Biosciences Q1 Earnings

Pacific Biosciences Q1 EPS $(0.37) Misses $(0.31) Estimate, Sales $33.20M Beat $32.82M Estimate